Please ensure Javascript is enabled for purposes of website accessibility

It's Time We Get Serious About Faster Drug Approval

By Sean Williams - Nov 27, 2012 at 2:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

We can and have to do better for patients with unmet medical needs and serious illnesses.

The Food and Drug Administration is the necessary evil that's there to keep the checks and balances in place for the drug innovation process -- but the regulatory agency is damned if it does and damned if it doesn't. When Merck's (MRK -1.54%) arthritis medication Vioxx was recalled in 2004 and linked to more than 27,000 cardiovascular events, the FDA was criticized for not seeing the drug's serious early warning signs. On the other hand, the simple fact that it takes an average of 12 years from conceptualization of a drug in a laboratory to eventual approval speaks of the ridiculously difficult process involved to get a drug approved. Like I said, damned if it does and damned if it doesn't.

We can do better
"Why are you bringing this up," you may be wondering? This one's a bit personal to me as I've personally witnessed the intangible costs that disease has exacted on family and friends.

I lost my mother to non-small-cell lung cancer in August 2010, long before Celgene's (CELG) Abraxane added NSCLC as an additional indication. Today, I'm writing this article from the hospital bedside of my good friend Scott Cruz who's been battling brain cancer for 23 years, since he was just 3 years old. Roche's (RHHBY 0.79%) Avastin was recently combined with his current treatment, Temodar, manufactured by Merck, to produce a positive progression-free survival benefit in phase 3 trials over just Temodar alone. However, this potential combination comes too little too late for Scott because of the rigorous FDA approval process -- even for already-approved drugs that are targeting additional indications.

I realize that I'm not the only person who's lost a loved one to a disease that seems to have discoveries emerging at a snail's pace, and I surely won't be the last, but the pace and pathways by which the FDA is requiring biotech companies to go from innovation to marketing is simply inadequate. We need to get serious about faster drug approval, and it needs to happen now.

Baby steps
We've seen some discernible steps to speed up the approval process for innovation to marketing with the passing of the Food and Drug Administration Safety and Innovation Act, or FDASIA. This bill, signed into law in July, will allow the FDA to collect user fees from brand-name drug makers, generic drug makers like Mylan (MYL) -- the biggest generic producer which had previously been exempt from any user fees -- and medical device companies, to conduct and expedite safety and efficacy reviews of crucial pipeline drugs and devices. 

One specific provision of the FDASIA was the TREAT Act, introduced by Sen. Kay Hagan. The specifics of the TREAT Act are that unmet and serious medical diseases will now face an accelerated review process in the attempt to get these potentially life-saving treatments to patients earlier. 

These are great steps, and I applaud the Senate, House of Representatives, and president for putting these provisions into law in order to get treatments to those who truly need it. But, just as this is a step in the right direction, it's also an arduously slow process that hasn't gone nearly far enough.

This can't be as good as it gets
To begin with, I'd like to point to my colleague Brian Orelli who hit one of my key gripes right on the head back in late September. We've seen a select few expedited approvals -- most notably Medivation's (MDVN) prostate cancer drug Xtandi, which was approved months ahead of its PDUFA date -- but where are the expedited non-approvals?  

It's understandable to assume that not every drug is going to meet the FDA's rigorous safety and efficacy criteria, but why can't we get this information back to the formulating companies earlier? Just like the theory of "If the black box can survive a plane crash, then why don't we make the entire plane out of the same material," I think to myself, if fast-track status gives a company a more intimate hand-in-hand approach to drug development, why can't we fast-track all drugs, use these user fees to expand the workforce of the FDA, and get biotech companies working side-by-side with FDA regulators to get drugs to market quicker? We could possibly eliminate half of all drug safety and manufacturing hold-ups, if not more!

Another factor that astounds me is that we've seen genome sequencing costs go from north of $10,000 just a decade ago to just $1,000. With the ability to accurately and rapidly turn genome data around in a day, why aren't we seeing biotechs, big pharmaceutical companies, and the FDA focusing on using this technology to move studies out of the lab even quicker than they are now? Realistically, we're losing three to four years on lab work and pre-clinical studies before they even make it to clinical trials. We have the technology to drastically shorten this time period, and regulators are effectively twiddling their thumbs.

There also has to be a better way of sharing information across the aisles -- and I'm not talking about Democrats and Republicans in this case. Specifically, I can't understand why we can't get the European Medicines Agency -- or EMA -- the FDA of Europe, and the FDA to cooperate to bring drugs to market quicker. I fully understand that the two agencies have varying goals, and approval in Europe is usually seen as easier than in the United States, but it's incredibly irritating to see drugs get held up for years in the U.S. approval process when they're already approved in Europe. These two agencies need to find a way to put their knowledge together and work as a team.

I'm open for change in many different respects, and these suggestions above are merely a combination of Brian's idea and my own ideas. What I can tell you is this: Having spent many months in and out of hospitals over the past three years, people like my mother and Scott have received great care, but they deserve and can/could have received better. The FDA and lawmakers are finally starting to take steps in the right direction, but we're only at the beginning of a major crossroads in the transformation of the drug approval process.

What suggestions do you have to expedite the FDA drug approval process? Post your thoughts, no matter how grandiose, in the comments section below.

With the loss of Singulair, does Merck have the pipeline necessary to replace this blockbuster? Get the answer to this question, and much more, by getting your copy of our latest premium research report on Merck. Packed with in-depth analysis on the opportunities and threats facing Merck -- and complete with a year of regular updates -- this report will give you the tools needed to make smart long-term investing decisions. Click here to learn more.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Medivation, Inc. Stock Quote
Medivation, Inc.
MDVN
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$92.31 (-1.54%) $-1.44
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$43.33 (0.79%) $0.34
Celgene Corporation Stock Quote
Celgene Corporation
CELG
Viatris Inc. Stock Quote
Viatris Inc.
MYL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.